Category: Medicine

Women using estrogen-only menopausal hormone therapy may experience a 35% reduction in Alzheimer’s pathology and a 39% decrease in dementia risk, according to a recent Stanford study.

A recent study conducted by researchers at Stanford University suggests that women who utilize estrogen-only menopausal hormone therapy (MHT) may have a significantly lower risk of developing Alzheimer’s disease and related dementia. Published on August 12 in the journal Neurology, the study analyzed post-mortem data from 21,462 participants, focusing on 258 women who reported using estrogen-only MHT compared to approximately 2,701 women who did not use any form of MHT.

The researchers examined the brains of the participants for indicators of Alzheimer’s disease, including amyloid plaques and neurofibrillary tangles, which are two hallmark changes associated with the condition. The findings revealed that women who had undergone estrogen-only therapy had a 35% lower likelihood of exhibiting Alzheimer’s pathology and a 39% reduced risk of developing dementia over their lifetimes.

Among some living participants, those who used estrogen-only therapy performed better on memory tests and demonstrated greater independence in daily activities. Biomarkers found in blood and cerebrospinal fluid corroborated these results, suggesting a potential protective effect of estrogen on cognitive health. The average age of participants in the study was 70 years.

The researchers noted that recent studies indicate menopausal hormone therapy may yield greater benefits when initiated during or shortly after menopause. However, since many women in this study began treatment at an older age, the results may underrepresent the potential advantages of starting therapy earlier.

These findings challenge previous research that associated menopausal hormone therapy with an increased risk of dementia. Co-author Jennifer Bruno, PhD, an instructor in psychiatry and behavioral sciences at Stanford, explained, “Estrogen has well-described neuroprotective effects in animal models. It plays a role in shifting amyloid toward the non-amyloidogenic pathway and promoting tau dephosphorylation—both amyloid and tau are hallmarks of Alzheimer’s disease.”

Bruno further elaborated that estrogen supports synaptic plasticity, reduces neuroinflammation, and maintains the integrity of the blood-brain barrier. Consequently, the observed reduction in Alzheimer’s pathology among estrogen-only users aligns with these mechanisms.

Despite these promising findings, the study is not without limitations. As an observational study, it can only establish an association rather than a direct cause-and-effect relationship between hormone therapy and reduced Alzheimer’s risk. Senior author Hadi Hosseini, PhD, an associate professor of psychiatry and behavioral sciences at Stanford, acknowledged that “it’s possible that women who used hormone therapy differed from non-users in ways we couldn’t fully measure, such as baseline health status or engagement with healthcare.”

Hosseini emphasized that while the research team made efforts to adjust for known confounding factors, observational data has inherent limitations. “By looking at where the actual damage is done—the brain—you can see where the Alzheimer’s-associated defining features are and how many of them are there,” he added.

Alzheimer’s disease remains the leading cause of dementia among older adults, with women accounting for approximately two-thirds of diagnoses. Although the study’s findings do not alter current clinical recommendations, Hosseini underscored the necessity for well-designed clinical trials to validate these observations and determine whether menopausal hormone therapy indeed has a protective effect on cognitive health.

Bruno reiterated the importance of further research, stating, “These results add meaningful, first-of-their-kind pathological evidence to a genuinely controversial area—but they are a signal for further study, not a reason to start or stop MHT for brain health.”

She called for prospective, biomarker-based trials that follow women before, during, and after menopause to better understand the effects of MHT on brain health. The study was funded by the National Institutes of Health.

According to Fox News, the implications of this research could pave the way for new approaches in managing cognitive health in postmenopausal women.

New research suggests that sildenafil, the active ingredient in Viagra, may help prevent cancer metastasis by limiting cholesterol access to cancer cells.

Sildenafil, the active ingredient in Viagra, may have unexpected benefits beyond its well-known use for erectile dysfunction. Recent research indicates that this medication could play a role in preventing cancer metastasis, offering new hope for cancer patients.

Originally developed to treat high blood pressure and angina, Viagra gained popularity for its ability to enhance blood flow during sexual stimulation. However, a new study published by the American Association for Cancer Research highlights its potential anti-cancer properties.

Researchers at the Weizmann Institute of Science in Israel, led by Dr. Yarden Ariav under the guidance of Professor Ayelet Erez, found that sildenafil may restrict the spread of cancer by limiting cancer cells’ access to cholesterol. This research involved a comprehensive analysis of human and mouse cancer cells, genetic experiments, and 20 years of health data from 5 million members of Clalit Health Services, Israel’s largest nonprofit healthcare provider.

The study revealed that sildenafil inhibits an enzyme known as phosphodiesterase type 5 (PDE5) and increases the levels of a signaling molecule called cyclic guanosine monophosphate (cGMP). This mechanism is responsible for dilating blood vessels, a feature that has made Viagra a successful treatment for erectile dysfunction.

Importantly, the researchers discovered that cGMP binds to a protein that transports cholesterol within cells, thereby reducing the availability of cholesterol for critical cellular functions. Cancer cells, which rely heavily on cholesterol for their growth and migration, are particularly vulnerable to this reduction.

Based on these findings, the research team proposed that combining Viagra-related drugs with statins—medications that lower cholesterol—could slow the spread of cancer by further limiting tumor cells’ access to both existing and newly produced cholesterol.

Dr. Erez commented on the implications of the study, stating, “We have uncovered a new biological pathway that links a well-known signaling molecule to cholesterol regulation within cells and shown how this pathway can be harnessed to interfere with the ability of cancer cells to form metastases.” She emphasized the importance of considering a patient’s overall metabolic state and existing medications when tailoring effective cancer therapies.

While the study’s findings are promising, the researchers acknowledged limitations, particularly regarding the use of mouse models, which may not always translate directly to human treatment. Additionally, the human evidence gathered is observational, indicating an association rather than a definitive cause-and-effect relationship.

As the medical community continues to explore the potential of sildenafil beyond its traditional use, these findings could pave the way for innovative approaches to cancer treatment. The study underscores the importance of a holistic view of patient care, focusing not only on the cancer itself but also on the broader context of the patient’s health.

For further insights, refer to the original study and statements from the researchers involved.

According to Fox News Digital, the implications of this research could significantly impact how cancer therapies are developed in the future.

Nirali N. Shah, a prominent Indian American pediatric oncologist, will lead the University of Maryland’s Pediatric/Adolescent and Young Adult Cell and Gene Therapy Program starting in September.

Nirali N. Shah, a distinguished Indian American pediatric oncologist, has been appointed to lead the Pediatric/Adolescent and Young Adult Cell and Gene Therapy Program at the University of Maryland School of Medicine. She will officially take on her new role as Professor and Director of the program in September.

In addition to her leadership position, Dr. Shah will also serve as the Associate Director for Translational Research at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) and will provide patient care at the University of Maryland Golisano Children’s Hospital (UMGCH), as announced by the university.

Dr. Shah is recognized for her expertise in blood cancers, hematopoietic stem cell transplantation, phase I clinical trials, and personalized immunotherapy for children and young adults. Currently, she holds the position of Head of the Pediatric Oncology Branch within the Hematologic Malignancies Section and serves as a Senior Investigator at the National Cancer Institute (NCI) Center for Cancer Research.

Her recruitment to UMGCH follows a significant $50 million donation from philanthropist Tom Golisano, made in October 2025. This donation marks the largest philanthropic contribution in the history of the University of Maryland Medical System (UMMS) and the University of Maryland, Baltimore (UMB).

“Dr. Shah’s recruitment is a powerful expression of our mission to save and improve the lives of children, in Maryland and well beyond,” stated UMGCH Director Steven J. Czinn. “Her renowned work in CAR T-cell therapy for children with treatment-resistant leukemia exemplifies how discovery and compassion come together to change outcomes for our most vulnerable patients.”

Dr. Shah’s commitment to developing targeted immunotherapies for complex, high-risk blood cancers in children, adolescents, and young adults underscores the vital connection between innovative research and patient-centered care.

She has played a key role in the development of CD22 CAR T-cells, which are engineered immune cells designed to target specific cancer cells. Her research has significantly advanced the understanding of the efficacy and side effects of CAR T therapy in pediatric patients. Additionally, she is the Principal Investigator for multiple active clinical trials, which encompass treatment, data analysis, and retrospective studies.

Dr. Shah has authored over 150 peer-reviewed research papers, many of which have been published in prestigious journals such as *Nature Medicine*, *Blood*, and the *Journal of Clinical Oncology*. At the NCI, she has co-chaired the Myeloid Malignancies Program Steering Committee and has served as an adjunct investigator in the Immune Deficiency Cell Therapy Program.

Her innovative contributions to the field have earned her several accolades, including the American Society of Gene & Cell Therapy (ASGCT) Outstanding New Investigator Award in 2026, the Presidential Early Career Award for Scientists and Engineers (PECASE) in 2025, and the Frank A. Oski Memorial Research Lectureship from the American Society of Pediatric Hematology and Oncology in 2024.

Dr. Shah received her medical degree from the University of Illinois and holds a master’s degree in health science with a focus on clinical research from Duke University. She completed her residency in the Harvard Combined Internal Medicine and Pediatrics Program at Massachusetts General Hospital and Boston Children’s Hospital, followed by a fellowship in pediatric hematology/oncology through the combined Johns Hopkins University-NCI program.

She is board certified in pediatric hematology/oncology, pediatrics, and internal medicine.

According to the university announcement, Dr. Shah’s leadership is expected to enhance the capabilities of the cell and gene therapy program, ultimately benefiting countless young patients facing challenging health conditions.

Full-body MRI scans are gaining attention for their potential to detect diseases early, but medical experts urge caution regarding their use in asymptomatic individuals.

Full-body scans are back in the spotlight following a recent revelation by former “Bachelor” contestant Josh Seiter, who disclosed that a preventive scan uncovered a brain tumor before any symptoms appeared. This incident has reignited discussions among medical professionals about the advantages and disadvantages of full-body MRI screenings.

Celebrity endorsements from figures like Kim Kardashian and Paris Hilton have further fueled public interest in these screenings, despite ongoing debates among healthcare experts regarding their efficacy for healthy individuals. Full-body scans utilize various imaging technologies, including magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET), as outlined by the Dana-Farber Cancer Institute. The primary aim of these scans is to identify early signs of diseases such as cancer and heart conditions.

Dr. Daniel Durand, chief medical officer at Prenuvo, one of the largest providers of full-body scans in the U.S., likened the scan to a “virtual physical.” He explained that a radiologist can examine the internal structures of the body in ways that traditional annual physicals cannot. Prenuvo’s MRI technology gathers extensive health data, which is then analyzed by two licensed providers who explain the findings and suggest next steps to optimize health.

However, insurance coverage for whole-body scans is typically limited. Dr. Mikhail Varshavski, known as “Dr. Mike,” a primary care physician and podcaster, noted that coverage varies significantly depending on the insurance plan and specific clinical guidelines. He pointed out that for general screening purposes, these tests are often not covered due to a lack of documented clinical benefits versus potential harms. Some coverage may be available for individuals with high-risk genetic syndromes or specific medical conditions.

Durand expressed hope that as more research is conducted, insurers will recognize the benefits of proactive healthcare approaches and expand coverage options. Prices for full-body scans can reach as high as $2,500, depending on the provider and selected options. The two leading companies in this field are Prenuvo, based in California, and Ezra, located in New York City.

Dr. Brett Osborn, a neurologist and longevity expert from Florida, has also discussed the potential benefits of full-body MRI scans. He emphasized that MRI technology allows for a comprehensive, non-invasive examination of the body, enabling the detection of various conditions, including cancers and vascular malformations like aneurysms, without the harmful radiation associated with CT scans.

Durand claimed that Prenuvo scans can identify many diseases based on internal changes detectable by MRI, often before symptoms manifest or before any signs are evident during a physical examination. He stated that early detection could lead to timely treatment, potentially preventing permanent damage from diseases such as cancers, infections, or aneurysms.

Despite these claims, Dr. Mike has not recommended MRI screening scans to his patients. He cited the high upfront costs and the absence of clear medical indications for broad screening in low-risk, asymptomatic individuals as reasons for his stance. He aligns with major medical organizations that do not endorse routine whole-body MRI screening for the general population.

Much of the popularity surrounding these scans can be attributed to celebrity endorsements, which Dr. Mike finds concerning. He noted that even when celebrities receive scans for free, it can create a misleading impression about the necessity and effectiveness of such screenings. He pointed out that companies cannot claim their tests save lives, leading to a situation where celebrities make personal claims that may not undergo the same scrutiny.

Dr. Marc Siegel, a clinical professor of medicine at NYU Langone Health and senior medical analyst for Fox News, also advises against full-body scans for patients. He believes that current technology is better suited for more targeted evaluations conducted by expert physicians who understand what they are looking for. Siegel cautioned that full-body scans might lead to unnecessary follow-ups for positive findings that may not be significant.

He also highlighted the high costs associated with these scans and the fact that they are often oversensitive. Siegel noted that the medical community is shifting towards more personalized healthcare approaches, enhanced by genetics and artificial intelligence, which will likely lead to more directed evaluations rather than broad full-body scans.

Dr. Mike outlined some significant risks associated with full-body scans, including false positives, overdiagnosis, and overtreatment. He also mentioned mental health risks, such as anxiety during the procedure and stress from incidental findings, which could exacerbate health-related worries. While some proponents argue that these scans can alleviate health-related anxiety, Dr. Mike remains skeptical, citing his clinical experience that suggests even clear scan results provide only temporary peace of mind.

A 2020 study indicated that imaging abnormalities are expected in about 95% of individuals screened, meaning that most will receive some form of finding, which could be distressing for those already prone to health anxiety.

During a podcast interview in 2025, Andrew Lacy, CEO of Prenuvo, acknowledged that long-term data on the effectiveness of these screening scans is still lacking. Dr. Mike reiterated that without clear data on the benefits and harms of such interventions, particularly for healthy individuals, he cannot recommend them widely.

Durand cited a recent study involving over 1,000 patients followed for one year, which found that 2.2% of Prenuvo patients had pathologically proven cancer, most of which were early-stage and for which there are no widely accepted screening exams. However, the FDA has echoed the concerns of many doctors, stating that there is currently no scientific evidence demonstrating that whole-body scanning of asymptomatic individuals provides more benefits than harms.

The FDA also warned about the relatively high radiation exposure associated with CT scans, emphasizing that while the risks are outweighed by the benefits of diagnostic scans, the advantages of whole-body screening for asymptomatic individuals remain questionable. They advise patients to carefully consider the potential risks and benefits of CT screening procedures and to discuss them with their physicians.

The American Academy of Family Physicians (AAFP) similarly recommends against full-body scans for early tumor detection in asymptomatic patients, reinforcing the need for caution in the use of these advanced imaging technologies.

As the conversation around full-body scans continues, it is essential for individuals to weigh the potential benefits against the risks and to seek guidance from qualified healthcare professionals.

According to Fox News.

Merck’s Lipfendra, the first oral PCSK9 inhibitor, has received FDA approval, demonstrating a significant reduction in LDL cholesterol levels for millions of Americans with high cholesterol.

Millions of Americans with high cholesterol now have a new treatment option following the FDA’s approval of Lipfendra, the first once-daily oral PCSK9 inhibitor. Merck, the New Jersey-based manufacturer of Lipfendra (enlicitide), announced the approval on Thursday.

Lipfendra works by blocking the action of PCSK9, a naturally occurring protein that plays a crucial role in how the liver removes LDL, commonly referred to as “bad” cholesterol, from the bloodstream. According to Dr. Marc Siegel, Fox News senior medical analyst, “PCSK-9 is a protein that works in the liver, preventing the recycling of LDL receptors, which results in increased bad cholesterol in the blood.” He noted that while this mechanism may have been beneficial in the past for hunter-gatherers, it now contributes to the formation of plaques that lead directly to heart disease.

The FDA has approved Lipfendra as an add-on treatment to diet and other LDL-lowering therapies for adults with high cholesterol, including those with inherited forms of the condition. In phase 3 clinical trials, Lipfendra demonstrated an impressive reduction in LDL cholesterol levels, achieving a decrease of approximately 56% to 60% when used in conjunction with statin therapy.

<p”This is around double the impact of statins,” Siegel remarked, highlighting the potential of Lipfendra to significantly enhance cholesterol management for patients.

Merck reported that the pill was generally well-tolerated during clinical trials, with the most common side effects being diarrhea and dizziness. Serious side effects and treatment discontinuations occurred at rates comparable to those in the placebo group.

Statins, which work by blocking an enzyme in the liver responsible for cholesterol production, are the most commonly prescribed medications for lowering cholesterol, according to the American Heart Association. While statins are effective for many individuals, some patients with very high cholesterol levels, inherited forms of high cholesterol, or those who experience adverse side effects from statins may require additional treatment options, such as a PCSK9 inhibitor like Lipfendra.

Previously, PCSK9 inhibitors such as Repatha and Praluent were only available as injections, a factor that experts believe may have contributed to their underuse. “Repatha, the injectable form, is very useful, with few side effects,” Siegel noted. “The oral form, Lipfendra, is also well-tolerated and just as effective.”

Despite the promising results, additional research is needed to determine whether Lipfendra can also reduce the risk of heart attacks, strokes, and cardiovascular deaths. Merck has indicated that results from a large clinical trial are expected to be available in 2029.

Dr. Siegel added, “Steve Nissen, longtime head of preventive cardiology at Cleveland Clinic, tells me that the lower the better when it comes to LDL cholesterol, especially in those at risk for heart disease.”

With the approval of Lipfendra, patients now have a new and effective option for managing high cholesterol, potentially transforming the landscape of cholesterol treatment.

According to Fox News, this development marks a significant advancement in the fight against high cholesterol and its associated health risks.

Senator Lindsey Graham’s recent death from an aortic dissection highlights a serious cardiovascular condition that has also claimed the lives of notable figures like John Ritter and Alan Thicke.

Senator Lindsey Graham’s unexpected passing has brought renewed focus to a rare but often fatal cardiovascular emergency known as aortic dissection. His death was attributed to an aortic dissection caused by arteriosclerotic cardiovascular disease, according to preliminary findings released by his office and the District of Columbia’s Office of the Chief Medical Examiner.

“An aortic dissection occurs when the layers of the aorta, the body’s largest artery, separate, leading to a tear in the inner layer,” explained Dr. Marc Siegel, a senior medical analyst for Fox News, who did not treat Graham. “This condition can develop suddenly, either in a matter of minutes or over several days, and may be difficult to recognize.” He noted that while some dissections can evolve gradually, symptoms often manifest abruptly.

Graham, who was 71 years old at the time of his death, is not alone in facing this life-threatening condition. Several other prominent individuals have also succumbed to aortic dissections, including actor John Ritter and television personality Alan Thicke.

John Ritter, best known for his role in the beloved sitcom “Three’s Company,” died from an aortic dissection on September 11, 2003. The John Ritter Foundation for Aortic Health reported that he was taken to the hospital after experiencing symptoms consistent with a type A aortic dissection. This type of dissection affects the ascending aorta near the heart and typically requires emergency surgery. At the time of his death, Ritter was filming “8 Simple Rules…for Dating My Teenage Daughter.” Initially treated for what was presumed to be a heart attack, he tragically passed away that same evening as his condition deteriorated.

The John Ritter Foundation expressed condolences to Graham’s family in a press release, emphasizing the importance of awareness surrounding aortic dissections. “These deaths underscore that aortic dissections are not a rare cause of death,” said Meredith Ford O’Neal, CEO of the foundation. “Deaths due to aortic dissections are preventable if individuals at risk are identified and properly treated. We hope this moment encourages people to learn the warning signs of aortic dissection, especially for family members of those who have experienced this condition.”

Another notable figure, Representative Doug LaMalfa from California, passed away on January 6, 2026, at the age of 65 due to complications from an aortic dissection. The Butte County Sheriff’s Office reported that cardiomegaly, or an enlarged heart, was also a significant factor in his death, which was ruled natural. LaMalfa underwent emergency surgery but unfortunately did not survive the procedure. A month later, the Sheriff’s Office confirmed that the cause of death was indeed complications related to an aortic dissection.

Alan Thicke, the actor famous for his role in “Growing Pains,” died from an aortic dissection on December 13, 2016, at the age of 69. Thicke reportedly experienced chest pain while playing hockey with his son and was subsequently taken to the hospital. The Los Angeles County coroner later determined that he died from a ruptured aorta caused by a type A aortic dissection. Dr. Grayson Wheatley, a Nashville-based heart surgeon, commented on Thicke’s case, noting that chest pain is often the first sign of a sudden tear in the aorta, which can develop rapidly.

“The pain associated with an aortic dissection is extreme,” Dr. Wheatley stated. “Patients describe it as so intense and sudden that it drops them to their knees. They feel an intense tearing or ripping sensation in their mid-upper back and/or chest.” Once a dissection occurs, it becomes a critical situation, as the condition can deteriorate quickly.

Dr. Neel Mansukhani, a vascular surgeon at Northwestern Medicine in Chicago, explained the life-threatening nature of this condition. “The aorta is the main blood vessel that comes off the heart, branching off to supply blood to all internal organs, arms, legs, and the brain,” he said. “The aorta consists of three layers, and a tear in the lining can cause these layers to separate, similar to paint peeling off a wall. The consequences depend on where the tear occurs.” He noted that an enlarged aorta or damage to the vessel wall from cardiovascular disease can increase the likelihood of an aortic dissection, with age and high blood pressure being the primary risk factors.

Type A dissections are particularly dangerous, as they occur near the heart and typically require emergency surgery within 24 hours if the patient is stable enough to undergo the procedure. In contrast, type B dissections, located further down from the heart, can also be life-threatening but do not always necessitate immediate surgery.

Although an aortic dissection can strike without warning, maintaining cardiovascular health and monitoring conditions such as high blood pressure can help reduce the risk, according to Dr. Mansukhani.

As the medical community continues to raise awareness about this serious condition, the deaths of public figures like Lindsey Graham, John Ritter, Alan Thicke, and Doug LaMalfa serve as poignant reminders of the importance of understanding the risks and symptoms associated with aortic dissections.

For more information on aortic dissections and related health topics, consult medical professionals or trusted health organizations.

According to Fox News.

The Justice Department’s recent healthcare fraud takedown highlights the growing issue of medical identity theft, which poses significant challenges for victims seeking to correct their medical records.

The Justice Department (DOJ) has charged 455 individuals in its annual National Health Care Fraud Takedown, a significant operation that addresses over $6.5 billion in alleged fraudulent claims. This year saw increased participation from state Medicaid units, with 90 of the accused being doctors or licensed medical professionals. While the DOJ has made these charges, prosecutors must still prove their cases in court.

Many of the fraudulent schemes involved the use of stolen medical identities. In response, prosecutors have added aggravated identity theft charges in cases spanning dozens of states. One notable case involved the co-owner of a Virginia mental health company who allegedly paid homeless individuals with hotel stays. Prosecutors claim the company used their Medicaid numbers to bill for crisis services that were never provided.

For victims whose identities have been misused, the closure of a case file does not necessarily mean the end of their troubles. Correcting corrupted medical records can be a daunting task. When someone else’s treatment records are mixed with your own, it can lead to incorrect information appearing in your medical chart. This can also deplete insurance benefits that victims may need in the future, making it far more complicated to resolve than simply canceling a credit card.

Medical identity theft occurs when an individual’s name, Social Security number (SSN), health insurance account number, or Medicare number is used by someone else to obtain medical services, fill prescriptions, or submit claims, according to the Federal Trade Commission (FTC). When care is billed under a victim’s name, the perpetrator’s health information can become intertwined with theirs. The FTC warns that such mixed records can adversely affect the quality of care a victim receives and the benefits they can access. Critical information such as blood type, drug allergies, diagnoses, or prescriptions belonging to a stranger could be included in a physician’s file before treatment.

Hospitals and insurers maintain the records that facilitate this type of fraud, and these records are frequently targeted. While not every healthcare breach results in fraud, it underscores the importance of safeguarding personal information. The value of insurance numbers, Medicare numbers, SSNs, and medical records can persist long after a breach notification is issued.

This past spring, NYC Health + Hospitals reported a data breach in which an intruder accessed files that may have contained health insurance information, medical details, biometric data, billing information, and other personal data. The breach affected approximately 1.8 million current and former patients and employees.

Once a name, SSN, insurance number, Medicare number, or medical record is sold on the criminal marketplace, it can be resold to individuals who bill under someone else’s identity. The FTC advises that health insurance and Medicare numbers should be protected with the same vigilance as payment cards.

Fraudulent medical claims can bypass the usual alerts that accompany credit checks, making it essential for individuals to remain vigilant. The FTC recommends that if a bill, explanation of benefits (EOB), or Medicare notice indicates care that was never received, victims should act quickly and maintain written records of all communications. They should contact their insurer or Medicare using the number on their card, not one from an unsolicited text, email, or voicemail.

Victims should request the provider’s name, date of service, claim number, and service details in writing, and also contact the provider to obtain the medical or billing records associated with the claim. Reporting the error to the insurer’s fraud department is crucial, as is filing a report at IdentityTheft.gov, which provides a recovery plan and necessary documentation for any fraudulent bills or collections that may arise later.

It is also important to keep copies of every bill, EOB, letter, portal message, police report, and case number. Victims should request records from every provider, clinic, pharmacy, lab, and insurer that the thief may have exploited, and report each error in writing. Under the Health Insurance Portability and Accountability Act (HIPAA), a provider generally has 30 days to grant access to records after a written request, with a possible 30-day extension.

However, correcting the records themselves can take longer. The Department of Health and Human Services (HHS) states that a covered provider or health plan typically has up to 60 days to respond to a request to amend a medical record, with a possible 30-day extension in certain circumstances. If the provider or plan created the erroneous information, they are obligated to amend any inaccurate or incomplete data.

There is a caveat, though: a provider may refuse to release records that contain a stranger’s information, citing privacy concerns. In such cases, victims should ask for the provider’s privacy officer or patient advocate. If access to records is denied or an explanation is not provided within the required timeframe, individuals can file a complaint with the U.S. Department of Health and Human Services Office for Civil Rights.

While a credit freeze can prevent new accounts from being opened, it does not address claims filed using a victim’s insurance number. Because medical identity theft can occur without impacting credit files, monitoring where personal information appears is a proactive way to address potential issues. Identity theft protection services can monitor the dark web, data broker sites, and people-search sites for exposed SSNs, driver’s license numbers, medical ID numbers, and email addresses. They can also track all three credit bureaus for medical collections and flag public-record changes associated with an individual’s name.

If misuse occurs, some services offer fraud resolution support to assist victims in requesting records, disputing fraudulent claims, and working with providers, insurers, and credit bureaus. Certain plans may also include identity theft insurance to cover eligible recovery costs. While no service can prevent every instance of medical identity theft, ongoing monitoring can help identify exposed information before fraudulent treatments affect a victim’s records and insurance.

Medical identity theft often strikes in an area that many individuals overlook: their health records. Unlike a stolen credit card, which can typically be canceled quickly, a stolen Medicare or insurance number can lead to fraudulent claims, incorrect diagnoses, and complications that persist long after the fraud case is resolved. It is crucial for individuals to regularly check their EOBs, Medicare Summary Notices, and insurer portals for any visits, prescriptions, or equipment they did not receive. Additionally, treating insurance cards with the same caution as payment cards is essential. Individuals should refrain from sharing their insurance number with anyone who contacts them unexpectedly with offers.

The most important step is to act swiftly. Victims should call their insurer or Medicare, request claim details, and formally request their medical records in writing. Filing a report at IdentityTheft.gov is also vital to ensure they have the necessary documentation in case of future fraudulent bills or collections.

Have you ever encountered a medical bill, insurance claim, or EOB for care you did not receive? Share your experiences with us at CyberGuy.com.

According to Fox News, the rise in medical identity theft underscores the importance of vigilance in protecting personal information.

Powassan virus, a rare tick-borne illness, has reached record highs in the U.S. in 2025, with 76 cases reported and no available vaccine, raising public health concerns.

Powassan virus, a rare and potentially fatal tick-borne illness, has been making headlines as cases in the United States soar to unprecedented levels. The virus can be traced back to a tragic case in 1958 involving a young boy in Canada, which ultimately led to its identification.

The disease is named after the Ontario town where it was first discovered. Lincoln Byers, a four-year-old boy, succumbed to an illness that baffled medical professionals at the time. Years later, researchers identified a tick carrying the same virus on a dead squirrel, shedding light on the mystery and foreshadowing a growing public health challenge.

According to data from the Centers for Disease Control and Prevention (CDC), 2025 has seen a record 76 diagnoses of Powassan virus in the U.S., a stark increase from the previous average of just seven to eight cases annually. The virus is primarily transmitted to humans through the bite of infected woodchuck ticks or deer ticks, with transmission peaking from late spring to mid-fall when tick populations are at their highest and outdoor activities increase.

Public health experts are sounding the alarm about the virus’s rapid transmission, which makes it particularly dangerous. Dr. Jorge P. Parada, a medical advisor at the National Pest Management Association in Chicago, emphasized the urgency of the situation. “One of the most dangerous aspects is its rapid transmission,” he stated. “Powassan can be transmitted in as little as 15 minutes after the infected tick bites, while Lyme disease usually requires a 36- to 48-hour attachment time for transmission.”

While Powassan remains rare compared to Lyme disease, its speed of transmission raises significant clinical concerns. Dr. Marc Siegel, a senior medical analyst for Fox News, confirmed that Powassan transmits significantly faster than Lyme disease, with an incubation period of one to four weeks before symptoms appear.

Initial symptoms of Powassan virus infection can include fever, headache, vomiting, and weakness. Some individuals may remain asymptomatic, according to the CDC. However, the virus can escalate to severe neurological complications, such as encephalitis (inflammation of the brain) and meningitis (inflammation of the membranes surrounding the spinal cord).

In severe cases, patients may experience confusion, loss of coordination, difficulty speaking, and seizures. Approximately 10% of Powassan cases that involve severe neurological disease are fatal, and many survivors face long-term neurological issues.

Currently, there are no specific medications or vaccines available to treat or prevent Powassan virus. Clinical care is limited to supportive therapy, which may include intravenous fluids and respiratory support. While anyone can develop severe illness from the virus, those at the highest risk include children, older adults, and individuals with compromised immune systems.

The rising number of Powassan virus cases underscores the need for heightened awareness and preventive measures as the tick season approaches. Experts urge the public to take precautions when spending time outdoors, particularly in areas where ticks are prevalent.

As the situation evolves, continued monitoring and research will be essential in addressing this emerging public health threat, according to Fox News.

Healthcare providers and advocates are invited to share their views on expanding the role of physician-led hospitals in Medicare, with a public comment period closing on June 9, 2026.

As the June 9 deadline approaches, the Centers for Medicare & Medicaid Services (CMS) is actively seeking input from healthcare providers, patient advocates, and industry groups regarding the future of physician-owned hospitals in the Medicare system.

This initiative marks the first time federal health regulators have formally requested public feedback on the potential for physician-led hospitals to participate more extensively in Medicare payment models. The agency is particularly interested in whether these hospitals should be allowed to voluntarily engage in the Transforming Episode Accountability Model (TEAM), a value-based care initiative designed to enhance patient outcomes while reducing costs.

The public comment period is part of CMS’s Fiscal Year 2027 Inpatient Prospective Payment System (IPPS) proposed rule, and it invites a wide range of stakeholders—including healthcare organizations, physicians, medical societies, and patient advocates—to share their perspectives on this significant issue.

Supporters of physician-led hospitals view this request as an opportunity to reassess longstanding restrictions that have hindered the growth of these facilities for over a decade. Dr. Carlos J. Cardenas, president of Physician-Led Healthcare for America, characterized CMS’s outreach as a pivotal change in the federal government’s stance on physician-led care.

“The landmark moment is the fact that for the first time, it appears that CMS is not asking whether physician-led hospitals should be included, but rather, how do we include them in the delivery of care and in how we can better serve our patients,” Cardenas stated.

He further emphasized that physician-led hospitals have consistently shown strong results for patients, asserting that they deliver higher quality care, greater efficiency, and improved patient satisfaction. Despite these advantages, Cardenas noted that access to these models remains limited for many patients, a situation he believes needs to change.

Under the proposed rule, CMS is soliciting input on various questions, including which physician-owned hospitals should qualify for participation, the necessity of regulatory waivers, safeguards to protect patient choice, and compliance management after participation periods conclude.

Advocates argue that expanding the role of physician-led hospitals could contribute to lowering healthcare costs while maintaining high standards of care. Research has indicated that physician leadership in healthcare organizations often correlates with higher quality ratings and better operational efficiency without compromising financial performance.

Cardenas described the request for information from CMS as a significant shift in policy discussions, suggesting that physician-led providers are now being invited to participate in conversations about healthcare delivery models in unprecedented ways. He believes that involvement in programs like TEAM would enable physicians to directly influence the design and evaluation of care models aimed at enhancing outcomes and resource utilization.

Proponents also contend that increasing the presence of physician-led hospitals could address concerns regarding consolidation in the healthcare sector. They argue that fostering greater competition may provide patients with more choices and stimulate innovation in care delivery.

Studies have shown that hospitals with strong physician leadership tend to achieve higher patient satisfaction and quality outcomes. Additionally, patient-centered care models have been linked to lower costs and improved efficiency.

However, the proposal has not been without its critics. Some healthcare organizations have expressed concerns about the implications of expanding physician-owned hospitals. Critics have raised issues related to patient selection, market competition, and the potential for overutilization of services. Not all healthcare organizations support the expansion of physician-owned hospitals.

In a joint statement, Ashley Thompson, Senior Vice President for Public Policy Analysis and Development at the American Hospital Association (AHA), and Don May, Executive Vice President of the Federation of American Hospitals (FHA), highlighted important limitations facing physician-owned hospitals.

“Previous analysis has also shown that POHs report on fewer quality measures and have higher re-admission measure penalties,” they stated. “Compared to full-service hospitals, POHs are limited in the scope of services offered, often specializing in one type of care, like cardiac or orthopedic surgery, and treating patient populations that are younger, more likely to be commercially insured, and present with less complex conditions.”

Thompson and May also pointed out that, unlike full-service community hospitals, physician-owned hospitals are not obligated to provide emergency care and often depend on nearby facilities for emergency services.

As CMS evaluates potential future policy changes, it is actively seeking stakeholder feedback on these critical issues. For advocates of physician-led care, this consultation represents a rare opportunity to influence the direction of Medicare policy.

With the public comment window nearing its close, healthcare professionals and patient groups are encouraged to submit their views on whether physician-led hospitals should play a more significant role in delivering care under federal healthcare programs, according to Source Name.

Researchers have developed a novel pancreatic cancer drug that nearly doubles survival time, yielding unexpected results that have surprised experts in the field.

A new breakthrough in the treatment of pancreatic cancer has emerged, with a novel drug demonstrating the potential to nearly double survival rates for patients. This significant advancement has caught the attention of medical professionals and researchers alike, who are expressing surprise at the results of the trial.

The drug, which has not yet been named in the reports, was tested in a clinical trial that included a diverse group of participants diagnosed with pancreatic cancer. The findings revealed that patients receiving the treatment experienced a marked increase in survival time compared to those receiving standard therapies.

Pancreatic cancer is known for its aggressive nature and poor prognosis, often diagnosed at an advanced stage when treatment options are limited. The introduction of this new drug could offer hope to many patients facing this challenging diagnosis.

Experts have noted that the results of the trial could lead to a reevaluation of treatment protocols for pancreatic cancer. The nearly doubled survival rate is a significant milestone, as it challenges previous expectations regarding the effectiveness of existing therapies.

In addition to the survival gains, researchers are also investigating the drug’s mechanism of action, which may provide insights into how it can be integrated into current treatment regimens. The potential for this drug to become a standard part of care for pancreatic cancer patients is being closely monitored by the medical community.

The trial’s findings have sparked discussions among oncologists and researchers, who are eager to learn more about the implications of this breakthrough. As further studies are conducted, there is hope that this drug could lead to improved outcomes for patients battling pancreatic cancer.

This development comes at a time when advancements in cancer treatment are increasingly crucial, as the disease remains one of the leading causes of cancer-related deaths worldwide. The promise shown by this new drug could pave the way for more effective therapies and better survival rates for patients in the future.

As the medical community continues to analyze the results of this trial, the excitement surrounding this breakthrough highlights the ongoing efforts to combat one of the most challenging forms of cancer. The potential for improved survival rates could change the landscape of pancreatic cancer treatment, offering renewed hope to patients and their families.

According to Fox News, the implications of this drug extend beyond just survival rates, as it may also influence the overall approach to treating pancreatic cancer in the coming years.

Researchers have made an accidental discovery revealing that H3N2 and H1N1 flu strains utilize distinct strategies to enter cells, paving the way for new prevention methods against influenza.

An unexpected breakthrough in a laboratory has unveiled new avenues for preventing influenza. While studying the replication mechanisms of the flu virus, researchers found that different strains utilize unique strategies to infiltrate human cells, according to a report by SWNS.

By targeting the specific molecules that these viruses depend on, scientists discovered they could effectively block the viruses from entering new cells and halt their replication. This research highlights the potential for developing improved preventive medications against seasonal influenza.

“The hope is that fundamental, curiosity-based research like this helps to pave the way for novel strategies to treat and prevent influenza infections,” said principal investigator Dr. Emily Bruce from the University of Vermont’s Larner College of Medicine.

Among the various strains of flu, H1N1 and H3N2 influenza A viruses are the most prevalent. However, current testing methods are unable to distinguish between these two strains, and clinical treatments remain the same for both. Despite the availability of vaccines and antiviral medications, Dr. Bruce emphasized the urgent need for more effective treatments to prevent the virus from spreading from cell to cell.

“You don’t get sick when a virus is in one cell,” she explained. “You get sick because a virus replicates itself and goes into many more cells.”

The study, published in *The Journal of Virology*, initially aimed to map how viral RNA segments are transported within cells to produce new viral particles. The research team utilized H1N1 and H3N2 viruses isolated from the nasal passages of patients who tested positive in 2022.

During their investigation, the researchers unexpectedly discovered a cellular pathway that could block the virus from entering lung cells. Their findings revealed that when a specific human protein known as Rab11B was depleted, H3N2 viruses were unable to enter human lung cells, while H1N1 viruses remained unaffected.

Using reverse genetics, the team mapped this defect and identified a novel, H3N2-specific role for Rab11B during the viral entry process. This discovery challenges the long-held scientific assumption that all flu viruses enter cells in the same manner.

“Viruses are like pirates from different countries hijacking someone’s ship,” Dr. Bruce remarked. “Different viruses, like different types of pirates, use different methods to get onboard.”

She further elaborated, “We had previously thought that all flu viruses used the same way to get into a cell, but we discovered that this is not true. H1N1 and H3N2 need different proteins to get in, and if you get rid of the right protein, a specific virus can’t get in.”

While these findings shed light on a critical cellular pathway for viral entry, the researchers acknowledged that the study was conducted using isolated cells. Further research is necessary to determine whether blocking the Rab11B protein is safe and effective within the complex environment of a live human respiratory system.

Dr. Bruce and her team are eager to conduct additional studies to ascertain whether the Rab11B dependency is a fundamental characteristic of H3N2 or if it is a trait unique to the currently circulating flu strains.

According to SWNS, this research could significantly influence future strategies for influenza prevention and treatment, potentially leading to more effective interventions against this widespread virus.

A recent study highlights a controversial drug that can significantly alleviate severe depression symptoms within hours of administration.

This week in health news, a range of topics captured attention, including a groundbreaking study on a controversial drug that has shown promise in treating severe depression.

Researchers have discovered that a single infusion of this drug can lead to rapid relief from severe depression symptoms, often within just a few hours. This finding has sparked discussions about the potential for new treatment options for individuals suffering from this debilitating condition.

In addition to the depression study, other health-related stories have emerged. Following Pam Bondi’s recent diagnosis, experts are discussing the prognosis for thyroid cancer and what it means for patients facing similar challenges.

Meanwhile, there has been a notable increase in emergency room visits related to tick bites, as health professionals warn of a potential surge in tick-borne diseases this season. Awareness and preventive measures are being emphasized to mitigate risks associated with these bites.

On a lighter note, a new study suggests that a popular fruit may offer protective benefits for skin health against sun exposure. This finding adds to the growing body of research on the health benefits of fruits and their role in overall wellness.

Dietary changes are also making headlines, with recent research indicating that certain adjustments can lead to a ‘younger’ biological age in older adults. This could have significant implications for aging populations seeking to maintain health and vitality.

In a related study, researchers have identified that filtered water consumed at specific ages could potentially add months to an individual’s lifespan decades later. Such findings highlight the long-term benefits of hydration and water quality on health.

Additionally, a study suggests that finding the right balance of sleep could contribute to a longer life. This research underscores the importance of sleep quality and its impact on overall health and longevity.

As the health landscape continues to evolve, the surge in interest surrounding peptides beyond GLP-1s has been noted. The FDA is considering easing access to these treatments, which could open new avenues for managing various health conditions.

Finally, researchers have identified that certain types of sitting may pose a greater risk for developing dementia. This revelation calls for a reevaluation of sedentary behaviors and their implications for cognitive health.

These stories reflect the dynamic nature of health research and the ongoing quest for better understanding and treatment of various health issues, according to Fox News.

The World Health Organization expresses deep concern over the rapid spread of a rare Ebola outbreak in eastern Congo, which has resulted in at least 134 deaths and over 500 suspected cases.

BUNIA, Congo — The World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus raised alarms on Tuesday regarding the “scale and speed” of a rare Ebola outbreak in eastern Congo. Authorities have reported a troubling increase in suspected deaths, now totaling at least 134, alongside more than 500 suspected cases.

The outbreak, caused by the Bundibugyo virus, has gone largely undetected for weeks following the first known death. Health experts and aid workers indicated that initial tests focused on a more common type of Ebola returned negative results, delaying the response to the outbreak. Currently, there are no approved treatments or vaccines for the Bundibugyo virus.

Congo’s Health Minister, Samuel Roger Kamba, confirmed at a press conference that 69 cases have been treated since the outbreak began. He emphasized the urgency of the situation, noting that the WHO has declared the outbreak a public health emergency of international concern, necessitating a coordinated response.

Ghebreyesus expressed his “deep concern” over the epidemic’s rapid escalation, particularly with cases emerging in urban areas, the deaths of healthcare workers, and significant population movement. The WHO plans to convene its emergency committee to address the crisis.

As of now, authorities have not identified “patient zero” in the outbreak. Dr. Anne Ancia, head of the WHO team in Congo, mentioned that the Erbevo vaccine, which is used for a different type of Ebola, is being considered for potential use. However, even if approved, it would take approximately two months for the vaccine to become available.

Currently, the U.S. Centers for Disease Control and Prevention (CDC) and the Africa CDC are not on the ground in Congo, but organizations such as Doctors Without Borders and the Red Cross are actively involved in the response efforts.

Dr. Ancia warned that the road ahead would be long, stating, “I don’t see that in two months we will be done with this outbreak.” The confirmed cases span across several regions, including the capital of Ituri province, Bunia, as well as Goma, Mongbwalu, Nyakunde, and Butembo, which collectively house over a million residents.

Among the confirmed cases is Dr. Peter Stafford, an American physician working in Bunia. He had been treating patients at a local hospital, and while three of his colleagues, including his wife, are not showing symptoms, the situation remains precarious.

The outbreak’s escalation can be traced back to the first reported death on April 24 in Bunia, where the body was subsequently repatriated to the Mongbwalu health zone, a densely populated mining area. Kamba noted that this action contributed to the outbreak’s rapid growth.

When another individual fell ill on April 26, samples were sent to Kinshasa for testing. However, initial tests focused on the more common Zaire strain of Ebola returned negative results, leading local authorities to mistakenly conclude that the virus was not present. Only laboratories in Kinshasa and Goma have the capacity to test for the Bundibugyo virus.

Benjamin Mbonimpa, a representative of the M23 rebel group controlling Goma, announced that they have established entry and exit points in the city and would manage funeral services should the outbreak continue to spread. He urged residents to resume their daily activities while prioritizing public safety.

On May 5, the WHO was alerted to approximately 50 deaths in Mongbwalu, including four healthcare workers. The first confirmation of Ebola came on May 14, highlighting significant failures in the surveillance system. Jean-Jaques Muyembe, a virologist at the National Institute of Bio-Medical Research, criticized the lack of action, stating, “Our surveillance system didn’t work.” He emphasized that the laboratory in Bunia should have continued testing and sent samples to the national laboratory.

Matthew M. Kavanagh, director of the Georgetown University Center for Global Health Policy and Politics, criticized the previous U.S. administration’s decision to withdraw from the WHO and cut foreign aid, which he argued undermined the surveillance systems necessary for early detection of such outbreaks.

In response to the crisis, the U.S. State Department has stated that it acted swiftly, providing $13 million in assistance for the outbreak response.

Ebola is known for its high contagion rates, transmitted through bodily fluids such as vomit, blood, or semen. The disease can be severe and often fatal. During a previous outbreak over a decade ago, more than 11,000 people died, many of whom were infected during community funerals.

Dr. Craig Spencer, an associate professor at Brown University and an Ebola survivor, noted the disease’s impact on caregivers, saying, “Ebola is very much a disease of compassion.” Symptoms include fever, headache, muscle pain, weakness, diarrhea, vomiting, stomach pain, and unexplained bleeding or bruising.

The rising number of cases has led to growing panic in Bunia, where residents are taking precautions. Noëla Lumo, a local resident who previously lived in Beni, a region affected by past outbreaks, has begun making protective masks by hand in response to the latest crisis.

Eastern Congo is already grappling with a humanitarian crisis and threats from armed groups that have caused significant displacement in Ituri over the past year. According to the U.N., the region has over 273,000 displaced individuals out of a total population of 1.9 million.

U.N. staff in the area have been instructed to work from home and avoid crowded spaces, according to a Bunia-based official who requested anonymity due to the sensitive nature of the situation.

Breaking the chain of transmission remains the most critical challenge, according to Muyembe. He stated, “Of the 17 epidemics we have experienced in Congo, 15 were brought under control simply by applying public health measures.” He emphasized that avoiding contact with bodily fluids is essential to stopping the epidemic.

For further updates on the situation, refer to reports from the Associated Press.

According to Associated Press, the outbreak continues to pose significant challenges for local health authorities and international organizations.

Silent heart attacks often present subtle warning signs weeks before a critical event, including unusual fatigue and chest discomfort. Recognizing these symptoms can be life-saving.

Heart attacks do not always manifest with sudden chest pain or dramatic collapse. In many instances, the body provides warning signs weeks before a critical emergency occurs. These symptoms are often mild, confusing, or dismissed as stress, fatigue, acidity, or lack of sleep.

A “silent” heart attack can occur without obvious symptoms, leaving many individuals unaware of their condition until a medical check-up or until the situation becomes serious. However, healthcare professionals emphasize that paying attention to early warning signs can be crucial in saving lives.

Here are six silent heart attack symptoms that may appear nearly 30 days before a significant cardiac event:

**Shortness of Breath**

Experiencing breathlessness while climbing stairs, walking short distances, or performing daily activities can be an early warning sign. Many people attribute this sensation to age, weakness, or lack of exercise. However, when the heart struggles to pump blood effectively, the lungs may not receive sufficient oxygen-rich blood, leading to breathing difficulties.

Some individuals may even feel breathless while lying down or during sleep. If this symptom becomes frequent without a clear explanation, it should not be overlooked.

**Abdominal Pain or Discomfort**

Heart issues do not always present as chest pain. Discomfort can sometimes radiate to the upper stomach area, mimicking gas, acidity, bloating, or indigestion. This symptom is particularly common among women and older adults.

Many people mistakenly take antacids and dismiss the pain, believing it is related to food. However, recurring stomach discomfort accompanied by sweating, nausea, or weakness may indicate an underlying heart problem.

**Chest Discomfort or Pain**

Not every heart attack begins with intense chest pain. In silent heart attacks, discomfort may manifest as mild pressure, tightness, heaviness, or burning sensations in the chest. Some individuals describe it as a squeezing feeling that comes and goes.

The discomfort may also radiate to the shoulders, arms, neck, jaw, or back. Even mild chest discomfort lasting several minutes should never be ignored, particularly if it recurs over several days.

**Insomnia or Sleep Disturbances**

Sudden sleep issues can sometimes be linked to heart health. Individuals who experience silent heart attacks often report difficulties sleeping, waking up frequently at night, or feeling restless before the emergency occurs.

Some may also awaken with chest pressure or breathing difficulties during sleep. Poor sleep can negatively impact blood pressure, stress hormones, and heart function, increasing the risk of cardiac problems.

**Anxiety or Unexplained Nervousness**

Many individuals experience unusual anxiety before a heart attack, characterized by a persistent sense of fear, nervousness, panic, or uneasiness without any clear cause. Symptoms may also include sweating, rapid heartbeat, dizziness, or a feeling that “something is wrong.”

Since anxiety symptoms can resemble heart symptoms, individuals often confuse one for the other. If sudden anxiety arises alongside physical discomfort, seeking medical attention is essential.

**Fatigue or Unusual Tiredness**

Extreme fatigue is one of the most common silent heart attack symptoms. A person may feel exhausted even after adequate rest, with simple activities like walking, cooking, or lifting light objects becoming increasingly challenging.

This fatigue occurs because the heart is not pumping blood efficiently, forcing the body to exert more effort. Persistent tiredness lasting days or weeks should not be ignored, especially when accompanied by breathing difficulties or chest discomfort.

Recognizing these silent heart attack symptoms is vital, as they often appear gradually and may initially seem harmless. Shortness of breath, unusual fatigue, abdominal discomfort, chest pressure, sleep disturbances, and unexplained anxiety can all signal that the heart requires medical attention.

If these signs persist for several days or become more frequent, consulting a healthcare professional promptly is the safest course of action. Listening to your body today could help prevent a major heart emergency tomorrow.

Disclaimer: This article is for general awareness and informational purposes only. It should not be considered medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional if you experience any symptoms or health concerns, according to The Sunday Guardian.

An NIH-funded study from the Cleveland Clinic suggests that testosterone may help suppress glioblastoma growth in men, potentially paving the way for new brain cancer treatments.

A recent study funded by the National Institutes of Health (NIH) and conducted at the Cleveland Clinic has revealed that testosterone may play a role in suppressing the growth of glioblastoma, one of the most aggressive forms of brain cancer. This groundbreaking research could open new avenues for treatment and clinical trials aimed at combating this deadly disease.

Published in the journal *Nature*, the study challenges long-standing beliefs regarding male hormones and their relationship with brain cancer. Researchers found compelling evidence indicating that testosterone may actually inhibit the growth of glioblastoma tumors in men, a finding that could significantly alter treatment strategies for this condition.

In their investigation, scientists explored the interactions between androgen hormones, including testosterone, and glioblastoma. The research team discovered that reducing testosterone levels in male mice led to accelerated tumor growth and diminished immune responses within the brain. Notably, glioblastoma is diagnosed more frequently in men than in women, prompting researchers to suspect that male hormones might contribute to the disease’s prevalence. However, these new findings suggest a contrary effect.

“This outcome is a welcome surprise and may potentially offer a lead for new treatments for a kind of cancer that is deadlier in men,” said Anthony Letai, a researcher involved in the study, in a statement released by the NIH.

The study indicated that testosterone may help regulate immune activity in the brain. When androgen levels decreased in laboratory models, the hypothalamus-pituitary-adrenal axis—a stress-response system—became overactive. This overactivity triggered inflammation and created an environment that suppressed the immune system, allowing tumors to grow more aggressively.

Additionally, the research team analyzed medical data from over 1,300 men diagnosed with glioblastoma using the NIH’s SEER cancer database. The findings revealed that men receiving testosterone supplementation for unrelated medical conditions had a 38% lower risk of death compared to those not on testosterone therapy. However, researchers cautioned that these results do not definitively prove that testosterone directly enhances survival rates in humans.

Justin Lathia, the senior author of the study, noted that the immune environment of the brain is markedly different from that of other body parts, making the effects of hormones more complex to predict. These findings arrive at a time when researchers are increasingly investigating why certain cancers exhibit different behaviors in men and women. NIH-funded studies have also been examining the influence of sex chromosomes and hormones on tumor biology and immune responses.

The next phase of research will involve clinical trials aimed at determining whether testosterone-based therapies could be safely administered to specific glioblastoma patients.

Industry experts have welcomed the study’s findings. Himanshu Shah, Executive Chairman of Marius Pharmaceuticals, which produces the testosterone therapy Kyzatrex, described the research as “momentous.”

“Though testosterone supplementation is not yet a standard of care, it should be considered based on the influential results of such a large study. Patients will benefit from this,” Shah stated.

Kyzatrex, which has received approval from the U.S. Food and Drug Administration (FDA), is indicated for adult men with low or deficient testosterone levels. Earlier this year, Marius Pharmaceuticals announced plans for a new post-marketing clinical study to evaluate a potential label expansion for Kyzatrex CIII capsules in men aged 65 to 80 suffering from hypogonadism. As men age, declining testosterone levels can exacerbate various health issues, impacting energy, muscle strength, mobility, metabolism, and overall quality of life. Through this study, researchers aim to gain a deeper understanding of how Kyzatrex may enhance health outcomes and daily functioning in older patients.

Testosterone therapy has been successfully utilized for nearly a century, including for women undergoing menopause treatment. However, its progress faced significant hurdles after testosterone was classified as a Schedule III controlled substance in the United States during the 1980s. Critics of this classification argue that it was influenced more by political pressures than by scientific evidence, despite opposition from the FDA and the American Medical Association at the time.

The implications of this NIH-funded study are profound, as they not only challenge existing perceptions of testosterone’s role in brain cancer but also highlight the potential for new therapeutic strategies to combat glioblastoma in men.

According to The American Bazaar, the findings could reshape treatment approaches and encourage further research into the relationship between male hormones and cancer.

Understanding early-stage glaucoma is crucial for managing eye health, especially for those with risk factors like high intraocular pressure.

Manvinder*, a 62-year-old college professor from Minnesota, recently visited his ophthalmologist for a routine eye examination. During the visit, he was informed that he had high intraocular pressure (IOP) in his left eye and would require laser treatment. Concerned about the implications of this diagnosis, particularly as a diabetic, he sought further advice.

High intraocular pressure, or ocular hypertension, occurs when the fluid pressure inside the eye exceeds the normal range, typically above 21 mm Hg. This condition is usually measured using tonometry and indicates a potential imbalance in the eye’s fluid drainage system. If left untreated, high IOP can lead to glaucoma, a serious eye disease that can damage the optic nerve and result in permanent vision loss.

The prevalence of glaucoma is on the rise, with estimates suggesting it will increase from 2.8% in 2024 to 3.5% by 2060, largely due to an aging population. However, it is important to note that high IOP is a risk factor rather than a disease itself. Manvinder was reassured that, since his ophthalmologist recommended a remedial procedure, there was no need for excessive worry.

So, what causes high intraocular pressure? According to Dr. Sharma, high IOP occurs when the aqueous humor—the clear fluid that fills the front chamber of the eye—cannot drain properly. This fluid nourishes the eye’s structures, including the lens, iris, and cornea, while also maintaining the necessary pressure to keep the eye’s structure intact.

For normal IOP to be maintained, the drainage system that allows aqueous humor to exit the eye must be functioning correctly. When this system is obstructed or inefficient, fluid can accumulate, leading to increased pressure within the eye.

When it comes to treatment options, Dr. Sharma strongly recommends laser treatment for managing high IOP. This approach is effective and is often performed in an office setting. In some cases, it can serve as a first-line therapy, allowing patients to reduce or even eliminate their reliance on daily eye drops.

Common laser procedures for treating high IOP include Selective Laser Trabeculoplasty (SLT), which is often used for open-angle glaucoma to enhance fluid drainage; Laser Peripheral Iridotomy (LPI), which creates a small opening in the iris for angle-closure glaucoma; and Laser Cyclophotocoagulation, which decreases fluid production in the eye.

Patients are encouraged to discuss the specific type of laser procedure with their ophthalmologist before proceeding. While laser treatments are generally safe, Dr. Sharma notes that patients may experience temporary side effects. Immediately following the procedure, some individuals may notice blurred vision, a gritty sensation, light sensitivity, or irritation. These symptoms typically resolve within a few hours, although they can persist for a few days. It is advisable to have someone drive you home after the procedure, as your ophthalmologist may prescribe anti-inflammatory drops to aid recovery.

One of the most concerning aspects of glaucoma is that it often presents no symptoms in its early stages. Regular eye exams are crucial for early detection. In later stages, individuals may experience blind spots in their vision, headaches, eye pain, or redness. Certain groups are at a higher risk for developing glaucoma, including those with high IOP, individuals who are farsighted or nearsighted, long-term steroid users, those with a history of eye injuries, thin corneas, thinning optic nerves, diabetes, migraines, high blood pressure, and individuals over 40 years old. Additionally, a family history of glaucoma and certain ethnic backgrounds, such as Asian, African, or Hispanic descent, can increase risk.

Interestingly, Dr. Sharma notes that yoga and meditation can serve as complementary therapies for managing glaucoma. Research indicates that consistent practice may lower IOP, reduce stress levels, and enhance overall quality of life, particularly through meditation. However, patients should avoid inverted yoga poses that could increase eye pressure, such as headstands, downward dog, plow pose, or raised legs against the wall.

For those seeking more information on glaucoma, Dr. Sharma recommends several reputable resources, including the Cleveland Clinic and Mayo Clinic websites, as well as the Glaucoma Research Foundation. These platforms provide valuable insights into the condition and its management.

If you have further questions or need personalized advice, you can reach out to Dr. Sharma at editor@indiacurrents.com.

*Name changed upon request.

Understanding early-stage glaucoma is essential for effective management and maintaining eye health, particularly for individuals with risk factors such as high intraocular pressure, according to India Currents.

New research from Memorial Sloan Kettering Cancer Center suggests that personalized mRNA vaccines may significantly improve outcomes for pancreatic cancer patients after surgery.

For decades, a diagnosis of pancreatic cancer has been associated with dismal statistics and limited treatment options, primarily revolving around invasive surgical procedures. However, recent clinical research from Memorial Sloan Kettering Cancer Center (MSK) is changing the narrative, demonstrating that messenger RNA (mRNA) technology, which gained prominence during the COVID-19 pandemic, can be repurposed to empower the body to target its own cancer cells.

Leading this groundbreaking study is Indian American surgeon-scientist Dr. Vinod Balachandran, who offers new hope for a specific group of patients who have historically faced bleak prognoses. Dr. Balachandran serves as the Director of the Olayan Center for Cancer Vaccines and has devoted his career to understanding the mechanisms behind the survival of certain “exceptional survivors”—patients who manage to defy the odds against this aggressive disease.

His research team has identified that these rare individuals possess tumors with unique protein markers known as neoantigens, which naturally signal the immune system to mount a defense. “We are essentially trying to replicate that natural immune success in every patient,” Dr. Balachandran explained. His innovative approach in precision oncology has garnered significant attention within the medical community.

The personalized treatment protocol begins with sequencing a patient’s tumor immediately following surgery to pinpoint these specific neoantigens. Within weeks, a custom mRNA vaccine is produced and administered, instructing the body’s “killer” T cells to recognize and eliminate any residual microscopic cancer cells.

The results from the Phase 1 trial, recently presented at the 2026 American Association for Cancer Research (AACR) annual meeting, are promising. Among the 16 patients who received the tailored vaccine, eight exhibited a strong immune response. Remarkably, six years later, nearly 90% of these responders remain alive and cancer-free, a stark contrast to the typical five-year survival rate of just 13% for pancreatic cancer.

This innovative vaccine, known as autogene cevumeran, functions as a sophisticated “wanted poster” for the immune system. By teaching T cells precisely what cancer cells look like, the treatment establishes a lasting internal surveillance mechanism. Notably, researchers observed that the vaccine-stimulated T cells remained active and detectable even after patients underwent follow-up chemotherapy.

While the study’s scale is small, its encouraging outcomes have set the stage for a global Phase 2 trial. For both the medical community and families affected by this formidable malignancy, this research signifies a transformative shift from traditional chemotherapy to a future where a patient’s own biological makeup serves as a powerful ally in their recovery.

As Dr. Balachandran and his team continue to explore the potential of personalized mRNA vaccines, the hope is that this innovative approach will pave the way for more effective treatments for pancreatic cancer and other challenging diseases, ultimately improving survival rates and quality of life for patients.

According to The American Bazaar, the implications of this research could redefine cancer treatment paradigms, emphasizing the importance of personalized medicine in oncology.

RFK Jr. advocates for easier access to peptides for wellness, prompting concerns from medical professionals about potential risks and implications for public health.

In a recent development, Robert F. Kennedy Jr. has expressed his support for making peptides more accessible, particularly in the realm of wellness treatments. This initiative has sparked a debate among healthcare professionals who are raising concerns about the implications of such a move.

Peptides, often touted for their potential anti-aging benefits, are short chains of amino acids that can play various roles in the body, including hormone regulation and immune function. Advocates argue that easier access to these substances could empower individuals to take charge of their health and wellness. However, doctors are cautioning against the unregulated use of peptides, highlighting potential health risks and the need for professional oversight.

Concerns have been raised regarding the safety and efficacy of these treatments, especially when used without medical supervision. Some healthcare providers warn that the use of peptides could lead to unintended side effects or mask underlying health issues. The medical community is urging a more cautious approach, emphasizing the importance of thorough research and clinical guidance before individuals pursue peptide therapies.

As the conversation around wellness and alternative treatments continues to evolve, the push for easier access to peptides reflects a growing trend towards self-directed health management. However, the potential risks associated with unsupervised use cannot be overlooked. Medical professionals are advocating for a balanced approach that prioritizes patient safety while still allowing for innovation in health and wellness.

In addition to the discussions surrounding peptides, other health topics have emerged recently. Doctors have identified a condition known as ‘buffalo hump,’ which can be an indicator of hidden health problems. This condition, characterized by a buildup of fat at the base of the neck, may signal issues such as Cushing’s syndrome or other metabolic disorders.

Moreover, popular weight-loss medications have come under scrutiny for their potential hidden side effects. As more individuals turn to these treatments for weight management, healthcare providers are emphasizing the need for comprehensive evaluations to ensure patient safety.

In the realm of personal health, Dr. Wendy Troxel has shared valuable relationship tips for couples dealing with chronic snoring, highlighting the importance of communication and understanding in maintaining healthy partnerships.

On another note, experts are warning that wearable fitness trackers, while designed to promote health, could have unintended consequences. The pressure to meet fitness goals may lead to anxiety or unhealthy behaviors, prompting a reevaluation of how such technologies are used.

Geographical factors are also playing a role in health outcomes, with studies suggesting that where individuals live can significantly influence their risk of cancer mortality. This underscores the importance of addressing environmental and social determinants of health in public health initiatives.

In a concerning revelation, lead contamination has been discovered in public parks across major cities, raising alarms about the safety of recreational spaces for families and children.

Additionally, emerging research indicates that an individual’s mindset and outlook on life may be linked to their risk of developing dementia. This highlights the potential impact of mental health and positive thinking on overall well-being.

As healthcare costs continue to rise, many Americans are finding themselves waiting overnight for access to free healthcare services. This situation reflects the growing disparities in healthcare access and affordability across the nation.

Lastly, the trend of unconventional beauty treatments has gained attention, with procedures like butt microneedling becoming popular among those seeking aesthetic enhancements. This particular treatment has been described as ‘desperate’ by some, illustrating the lengths individuals may go to achieve their desired appearance.

As discussions around health and wellness continue to evolve, it is crucial for individuals to stay informed and consult with healthcare professionals before making decisions about treatments and lifestyle changes. The balance between innovation and safety remains a key consideration in the ongoing dialogue about personal health.

According to Fox News, the implications of RFK Jr.’s advocacy for peptide access are still unfolding, and the medical community remains vigilant in addressing the potential risks involved.

Research indicates that weight gain during one’s 20s poses significant long-term risks for premature death, highlighting the importance of early obesity prevention strategies.

A recent study involving over 620,000 individuals has revealed that weight gain in one’s 20s may carry disproportionately high and lasting risks of premature death later in life. This research challenges the common perception that weight management is primarily a concern for middle-aged individuals.

The study, published in the journal eClinicalMedicine, analyzed data from the Obesity and Disease Development Sweden project. It found that the earlier obesity sets in, the greater the risk of early mortality. According to Tanja Stocks, a professor at Lund University and one of the researchers, “The most consistent finding is that weight gain at a younger age is linked to a higher risk of premature death later in life, compared with people who gain less weight.”

Specifically, developing obesity between the ages of 17 and 29 was associated with a 70% higher risk of early death compared to those who gained weight later in life. While weight gain during adulthood, particularly between the ages of 30 and 60, also correlated with increased death rates, the associations were generally weaker.

Huyen Le, a doctoral student at Lund University and the study’s first author, suggested that one reason for the heightened risk associated with early-onset obesity is the prolonged exposure to the biological effects of excess weight. “When weight gain happens in the 20s, the blood vessels, liver, and metabolic systems endure obesity-related strain for decades longer than someone who gains the same weight in their 50s,” Le explained.

The study identified type 2 diabetes as the leading cause of death linked to early-onset obesity. Other significant health risks included high blood pressure, liver cancer in men, and uterine cancer in women.

Researchers tracked participants’ weight trajectories over more than 50 years, focusing on three specific age windows: 17 to 29, 30 to 44, and 45 to 60. Using a body mass index (BMI) of 30 or higher to define obesity, the team compared weight data against Sweden’s national death registry.

After adjusting for various factors, including smoking habits and marital status, the trend indicated that while becoming obese later in life still posed risks, the danger compounded the longer individuals remained obese. Stocks emphasized the need for caution in interpreting risk figures, stating, “We shouldn’t get too hung up on exact risk figures. They are rarely entirely accurate, as they are influenced, for example, by the factors taken into account in the study and the accuracy with which both risk factors and outcomes have been measured.”

The researchers concluded that their findings underscore the importance of early and sustained obesity prevention strategies. However, they also noted that additional research is necessary to understand the effects of early-onset obesity in different populations, as this study was conducted in Sweden.

According to Fox News, the implications of this research may prompt a reevaluation of public health strategies aimed at combating obesity, particularly among younger individuals.

New research indicates that newly developed anemia may significantly increase the risk of cancer diagnosis and all-cause mortality within 18 months, according to a study published in BMJ Journals.

Anemia, a prevalent blood disorder, has been identified as a potential major risk factor for cancer development. A recent study from Sweden aimed to determine whether newly developed anemia serves as an early warning sign for cancer or increased mortality from any cause. The findings were published in BMJ Journals and analyzed registry data from over 380,000 Swedish adults, half of whom had newly developed anemia, while the other half were matched by age and gender but did not have the condition. All participants were over 18 years old and cancer-free at the study’s outset.

The results revealed that individuals with incident anemia—new cases identified over a specified period—exhibited a significantly higher likelihood of receiving a cancer diagnosis, particularly within the first three months. Specifically, 6.2% of men and 2.8% of women with newly developed anemia were diagnosed with cancer during this timeframe.

Moreover, those with anemia faced a considerably elevated risk of death during the 18-month follow-up period. The study also found that specific types of anemia were linked to disease progression and mortality rates. Microcytic anemia, characterized by smaller-than-normal red blood cells, was more frequently associated with cancer, especially cancers affecting the digestive system and blood. In contrast, macrocytic anemia, where red blood cells are larger than normal, showed a stronger correlation with overall mortality rather than cancer specifically.

The researchers concluded that new-onset anemia is a “strong and sustained risk marker” for both the incidence of cancer and all-cause mortality. Elinor Nemlander, the lead author of the study and a researcher at the Department of Neurobiology, Care Sciences and Society at the Karolinska Institutet, commented on the findings in a press release from the Swedish medical university. She noted, “We found that both the risk of cancer and the risk of death are highest during the first months after anemia is detected, but that the increased risk persists later during follow-up as well.” Nemlander emphasized that these findings suggest anemia may indicate an underlying disease rather than being a condition in its own right.

In an interview with Fox News Digital, Nemlander highlighted that measurements such as red blood cell size are already “routinely available” in primary care settings. She pointed out that the study underscores the potential for utilizing existing data to identify early risks. “At the same time, the elevated risks persist over time, underscoring the need for structured follow-up and clear plans for continued evaluation, even when cancer is not initially identified,” she added.

It is important to note that the study was observational, indicating an association rather than establishing a direct causal relationship between anemia and cancer or death. Additionally, the research did not account for all causes of anemia, including factors such as alcohol use, malnutrition, chronic liver disease, inflammatory conditions, and gynecological blood loss. Nemlander also mentioned that some results might be influenced by who undergoes testing, underlying illnesses, and variations in how anemia is assessed across different healthcare settings.

As the medical community continues to explore the implications of these findings, the study serves as a reminder of the importance of monitoring blood health and the potential risks associated with newly developed anemia. The insights gained from this research may lead to improved early detection strategies and better patient outcomes in the future, according to BMJ Journals.